Barclays PLC Purchases 126,503 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

Barclays PLC grew its holdings in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 182.6% in the third quarter, Holdings Channel.com reports. The firm owned 195,793 shares of the medical instruments supplier’s stock after buying an additional 126,503 shares during the period. Barclays PLC’s holdings in OraSure Technologies were worth $836,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently modified their holdings of the business. Geode Capital Management LLC lifted its stake in shares of OraSure Technologies by 1.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,797,814 shares of the medical instruments supplier’s stock valued at $7,678,000 after buying an additional 32,929 shares in the last quarter. Jane Street Group LLC raised its holdings in OraSure Technologies by 6.4% during the 3rd quarter. Jane Street Group LLC now owns 296,194 shares of the medical instruments supplier’s stock valued at $1,265,000 after acquiring an additional 17,758 shares during the period. Virtus Investment Advisers Inc. purchased a new stake in shares of OraSure Technologies during the third quarter worth $392,000. Systematic Financial Management LP boosted its holdings in shares of OraSure Technologies by 14.9% in the third quarter. Systematic Financial Management LP now owns 1,252,112 shares of the medical instruments supplier’s stock worth $5,347,000 after acquiring an additional 162,364 shares during the period. Finally, Jacobs Levy Equity Management Inc. grew its position in shares of OraSure Technologies by 66.5% in the third quarter. Jacobs Levy Equity Management Inc. now owns 524,950 shares of the medical instruments supplier’s stock valued at $2,242,000 after purchasing an additional 209,580 shares in the last quarter. Hedge funds and other institutional investors own 93.50% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, January 9th.

OraSure Technologies Trading Up 2.5 %

OSUR stock opened at $3.76 on Thursday. The firm has a 50 day moving average of $3.83 and a 200-day moving average of $4.10. The firm has a market capitalization of $280.47 million, a P/E ratio of 25.07 and a beta of 0.05. OraSure Technologies, Inc. has a 12 month low of $3.52 and a 12 month high of $8.33.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02. The firm had revenue of $39.92 million during the quarter, compared to the consensus estimate of $38.97 million. OraSure Technologies had a net margin of 5.07% and a return on equity of 3.55%. The business’s quarterly revenue was down 55.2% compared to the same quarter last year. During the same period last year, the firm earned $0.27 EPS. Sell-side analysts predict that OraSure Technologies, Inc. will post -0.08 EPS for the current year.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.